Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

By sjmartinez • August 16, 2023

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-416. doi: 10.1164/rccm.202306-0944OC. PMID: 37364283.

Tags: COPD, dual PDE3 and PDE4 inhibitor, ensifentrine, nebulized therapy, Publications, Pulmonary, Critical Care & Sleep Medicine

Prediction of Early Neoadjuvant Chemotherapy Response of Breast Cancer through Deep Learning-based Pharmacokinetic Quantification of DCE MRI

Wu C, Wang L, Wang N, Shiao S, Dou T, Hsu YC, Christodoulou AG, Xie Y, Li D. Prediction of Early Neoadjuvant Chemotherapy Response of[...]

Guideline-directed medical therapy and in-hospital mortality in acute coronary syndrome patients with advanced renal dysfunction: analysis of two nationwide retrospective cohort studies

Jin Z, Aa G, Guo Y, Liu H, Sun H, Li Z, Ma M, Fonarow G, Gao Y, Zhao D, Yang Q, Zhou X; CCC-AF[...]

Three-Dimensional Printing of the Human Pericardium to Facilitate Understanding of the Pericardial Reflections, Recesses, and Sinuses

Miyazaki Y, Rimmer M, Peacock WJ, Xu S, Shivkumar K, Mori S. Three-Dimensional Printing of the Human Pericardium to Facilitate Understanding of the Pericardial Reflections,[...]